Literature DB >> 15248755

Clusters of transmembrane residues are critical for human prostacyclin receptor activation.

Jeremiah Stitham1, Aleksandar Stojanovic, Lauren A Ross, Anthony C Blount, John Hwa.   

Abstract

Relaxation of vascular smooth muscle and prevention of blood coagulation are mediated by ligand-induced activation of the human prostacyclin (hIP) receptor, a seven-transmembrane-domain G-protein-coupled receptor (GPCR). In this study, we elucidate the molecular requirements for receptor activation within the region of the ligand-binding pocket, identifying transmembrane residues affecting potency. Eleven of 30 mutated residues in the region of the ligand-binding domain exhibited defective activation (decreased potency). These critical residues localized to four distinct clusters (analysis via a rhodopsin-based human prostacyclin receptor homology model). Residues Y75(2.65) (TMII), F95(3.28) (TMIII), and R279(7.40) (TMVII) comprised the immediate binding-pocket cluster and were shown to be essential for proper receptor activation, compared to equivalent expression levels of the wild-type hIP (WT EC(50) = 1.2 +/- 0.1 nM; Y75(2.65)A EC(50) = 347.3 +/- 62.8 nM, p < 0.001; F95(3.28)A EC(50) = 8.0 +/- 0.6 nM, p < 0.001; R279(7.40)A EC(50) = 130 +/- 63.0 nM, p < 0.001). Residues S20(1.39) (TMI), F24(1.43) (TMI), and F72(2.62) (TMII) were localized to a cluster involving P17(1.36), a critical residue thought to facilitate transmembrane movement during changes in activation conformation. A third cluster formed around amino acid D60(2.50) (TMII), containing the highly conserved (100% of prostanoid receptors) D288(7.49)/P289(7.50) motif located in TMVII. Last, a large hydrophobic cluster composed of aromatic residues F146(4.52) (TMIV), F150(4.56) (TMIV), F184(5.40) (TMV), and Y188(5.44) (TMV) was observed away from the ligand-binding pocket, but still necessary for hIP activation. These results assist in delineating the potential molecular requirements for agonist-induced signaling through the transmembrane domain. Such observations may be generally applicable, as many of these clusters are highly conserved among the prostanoid receptors as well as other class A GPCRs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15248755     DOI: 10.1021/bi0496788

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  Comprehensive biochemical analysis of rare prostacyclin receptor variants: study of association of signaling with coronary artery obstruction.

Authors:  Jeremiah Stitham; Eric Arehart; Larkin Elderon; Scott R Gleim; Karen Douville; Zsolt Kasza; Kristina Fetalvero; Todd MacKenzie; John Robb; Kathleen A Martin; John Hwa
Journal:  J Biol Chem       Date:  2010-12-28       Impact factor: 5.157

2.  Prediction of the 3D structure and dynamics of human DP G-protein coupled receptor bound to an agonist and an antagonist.

Authors:  Youyong Li; Fangqiang Zhu; Nagarajan Vaidehi; William A Goddard; Felix Sheinerman; Stephan Reiling; Isabelle Morize; Lan Mu; Keith Harris; Ali Ardati; Abdelazize Laoui
Journal:  J Am Chem Soc       Date:  2007-08-11       Impact factor: 15.419

3.  By interacting with the C-terminal Phe of apelin, Phe255 and Trp259 in helix VI of the apelin receptor are critical for internalization.

Authors:  Xavier Iturrioz; Romain Gerbier; Vincent Leroux; Rodrigo Alvear-Perez; Bernard Maigret; Catherine Llorens-Cortes
Journal:  J Biol Chem       Date:  2010-07-30       Impact factor: 5.157

4.  New insights into human prostacyclin receptor structure and function through natural and synthetic mutations of transmembrane charged residues.

Authors:  J Stitham; E Arehart; S R Gleim; N Li; K Douville; J Hwa
Journal:  Br J Pharmacol       Date:  2007-08-20       Impact factor: 8.739

5.  Prostacyclin analogs inhibit fibroblast contraction of collagen gels through the cAMP-PKA pathway.

Authors:  Koichiro Kamio; Xiangde Liu; Hisatoshi Sugiura; Shinsaku Togo; Tetsu Kobayashi; Shinsaku Kawasaki; Xingqi Wang; Lijun Mao; Youngsoo Ahn; Cory Hogaboam; Myron L Toews; Stephen I Rennard
Journal:  Am J Respir Cell Mol Biol       Date:  2007-03-15       Impact factor: 6.914

Review 6.  Prostacyclin receptor/thromboxane receptor interactions and cellular responses in human atherothrombotic disease.

Authors:  Scott Gleim; Zsolt Kasza; Kathleen Martin; John Hwa
Journal:  Curr Atheroscler Rep       Date:  2009-05       Impact factor: 5.113

7.  Novel signaling pathways promote a paracrine wave of prostacyclin-induced vascular smooth muscle differentiation.

Authors:  Zsolt Kasza; Kristina M Fetalvero; Min Ding; Robert J Wagner; Klara Acs; Anthony K Guzman; Karen L Douville; Richard J Powell; John Hwa; Kathleen A Martin
Journal:  J Mol Cell Cardiol       Date:  2009-01-23       Impact factor: 5.000

8.  The endothelium and its role in regulating vascular tone.

Authors:  Aamer Sandoo; Jet J C S Veldhuijzen van Zanten; George S Metsios; Douglas Carroll; George D Kitas
Journal:  Open Cardiovasc Med J       Date:  2010-12-23

9.  G protein Galphai functions immediately downstream of Smoothened in Hedgehog signalling.

Authors:  Stacey K Ogden; Dennis Liang Fei; Neal S Schilling; Yashi F Ahmed; John Hwa; David J Robbins
Journal:  Nature       Date:  2008-12-18       Impact factor: 49.962

10.  High throughput mutagenesis for identification of residues regulating human prostacyclin (hIP) receptor expression and function.

Authors:  Anke Bill; Elizabeth M Rosethorne; Toby C Kent; Lindsay Fawcett; Lynn Burchell; Michiel T van Diepen; Anthony Marelli; Sergey Batalov; Loren Miraglia; Anthony P Orth; Nicole A Renaud; Steven J Charlton; Martin Gosling; L Alex Gaither; Paul J Groot-Kormelink
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.